Navigation Links
Transdel Enrolls First Patient for Ketotransdel(TM) Phase 3 Clinical Trial
Date:9/22/2008

LA JOLLA, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on developing non-invasive, topically administered medications, today announced it has enrolled its first patient in the Phase 3 registration trial for Ketotransdel(TM). Ketotransdel(TM), a novel analgesic and anti-inflammatory topical cream, contains 10% ketoprofen (a non-steroidal anti-inflammatory drug, "NSAID"), and is intended for use in the treatment of acute pain from musculoskeletal conditions.

The Ketotransdel(TM) Phase 3 registration study entitled: "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel(TM) in the Treatment of Pain Associated with Mild to Moderate Acute Soft Tissue Injury," will be conducted at approximately 25 to 35 sites in the United States and potentially in Canada. The Company expects to enroll approximately 350 patients of which 50% will be provided Ketotransdel(TM) and 50% a placebo vehicle. The Phase 3 study currently has three sites that are actively screening for patients. It is expected that the majority of the sites will be activated during October and November. The Company expects to report top-line results in the second half of 2009.

In the Phase 3 study, the primary efficacy endpoint will be the difference in the change of baseline pain between Ketotransdel(TM) and placebo at Day 3. This endpoint is measured by using the Visual Analogue Scale (VAS), a validated and widely used scale for recording pain which 0 indicates "no pain" and 100 indicates "the worst imaginable pain." The secondary endpoints will include safety assessments and other efficacy parameters measured by VAS at Day 3 and Day 7. In addition to evaluating for efficacy and safety over the one week period, the study will also assess safety at one week post-treatment.

"We are excited about reaching
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. Transdel Initiates Ketotransdel(TM) Phase 3 Clinical Program for Pain
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
7. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014  As physicians ... to digital communication channels to learn about new ... finding – from a new report by global ... – shows that communicating via a customized mix ... provides the best opportunity to engage with physicians. ...
(Date:9/23/2014)... -- Enable Injections , developer of a novel ... and nearly painless for patients to self-inject large-dose biologic ... named winner of the ,Buzz of BIO Investor Forum, ... Enable is one of only two ,Buzz ... votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... 2014 Avillion LLP, a ... of Jarrod Longcor as Chief Business ... for structuring, negotiating and executing successful strategic alliances, ... providing management and strategic leadership to the organisation. ... team. Mr Longcor brings to Avillion ...
Breaking Medicine Technology:As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... Intra-Cellular Therapies, Inc. (ITI),today announced it has initiated ... using its drug candidate ITI-722. ITI-722 acts predominantly,as ... important new,approach to the treatment of SMI. Because ... modulatory activities, ITI believes, ITI-722 can be,used not ...
... Research Is a Winning Pursuit, WASHINGTON, Dec. ... L. Trull President, Foundation for Biomedical,Research:, Biomedical ... of pursuit" in 1980 earned Mario Capecchi a ... setback, the Harvard-educated genetics professor,persisted toward his goal. ...
Cached Medicine Technology:Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4Nobel Prize-Winning Discovery 2Nobel Prize-Winning Discovery 3
(Date:9/23/2014)... The Fit Body Boot Camp franchise is known throughout ... and their community outreach. The new Rockville Fit Body Boot ... of the company’s new fitness boot camp in ... is excited about the grand opening, because of the opportunity ... honor the memory of emergency workers who sacrificed their lives ...
(Date:9/23/2014)... 2014 Maturo Medical Weight and ... announced Dr. Lisa Maturo has received certification in ... Worldlink Medical Academy. Dr. Maturo is one of ... this credential. , World-renowned bioidentical hormone replacement ... the rigorous training course, which trained participants in ...
(Date:9/23/2014)... 23, 2014 Wohl Associates ... packaging equipment, has recently taken delivery of used industrial ... include mixers, sheeters, and equipment for producing gnocchi and ... Toresani unit and a La Parmigiana mixer/extruder. With a ... a mixing tank that is 17” wide, 28” long ...
(Date:9/23/2014)... 23, 2014 Hope For The Warriors® ... Celebration to be hosted in Boston, Massachusetts on Sunday, ... Amphitheater. This signature event honors the courage of our ... the fallen. Proceeds from the evening will benefit Hope ... a sense of self, restoring the family unit, and ...
(Date:9/23/2014)... Los Angeles, CA (PRWEB) September 23, 2014 ... launched sales funnel building software application has created a ... commotion surrounding the launch of this new software has ... published an investigative review for her readers. ... such as site design, programming and development can be ...
Breaking Medicine News(10 mins):Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 2Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 3Health News:Doctor Lisa Maturo of Maturo Medical Obtains Expert Certification in BioIdentical Hormone Replacement Therapy from World Link Medical 2Health News:Used Industrial Pasta Machinery Now Available at Wohl Associates 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:ClickFunnels 2.0 – Review Of Russell Brunson’s Sales Funnel Building Software Released 2
... Group,Inc. (Amex: QGP ) (http://www.QuantumMD.com ), ... Noel J. Guillama, President &,CEO, will present at ... p.m. (Pacific) on Monday, August 18, 2008 at ... Guillama will give a 23-minute presentation regarding The ...
... a national survey,of adults, 60 percent of Hispanic American ... is the #1 fatal disease among women.,Further, nearly half ... greater than that of Caucasian women. Dania Rich-Spencer, Vice,President ... the Go,Red For Women, founded by the American Heart ...
... getting infected cells to drop their guard according to ... a catalyst to a cancer-busting reaction which calls up an ... Cancer adapts quickly to traditional drugs which attack infected cells ... of defence using ruthenium as a catalyst to a reaction ...
... School of Medicine, Fox Chase Cancer Center and ... that will speed the translation of medical and ... , As part of the agreement, the ... Translational Medicine, based at Temple, to design and ...
... Program to Increase Breast and ... Cervical Cancer Screening Rates, COLUMBIA, ... care guidance company, today announced the,launch of their Women,s Health ... to help increase the,prevention and early detection of breast and ...
... all evidence of disease in selected patients with cancer ... the first published report from an ongoing clinical trial. ... Clinical Cancer Research, (published online August 12) researchers ... targeted radiation therapy had completely controlled all signs of ...
Cached Medicine News:Health News:The Quantum Group to Present at the Noble Financial Equity Conference 2Health News:The Quantum Group to Present at the Noble Financial Equity Conference 3Health News:Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 2Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 3Health News:Resolution Health Introduces Women's Health and Wellness Action Campaign 4Health News:Targeted radiation therapy can control limited cancer spread 2Health News:Targeted radiation therapy can control limited cancer spread 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: